Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
Randomized phase III trial to compare the effectiveness of low, intermediate, and high dose
suramin in treating men with stage IV prostate cancer that is refractory to hormone therapy.
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop
growing or die. It is not yet known which regimen of suramin is more effective for prostate
cancer.
Phase:
Phase 3
Details
Lead Sponsor:
National Cancer Institute (NCI)
Collaborators:
Eastern Cooperative Oncology Group Southwest Oncology Group